that those of you who like meat, eggs, and dairy are four times more likely to die from diabetes. Boosting antibody production seven-fold, but this is in vitro, in a Petri dish.
So he really wanted to get vaccinated. Many of the antibody tests out there are not particularly good at actually giving you
We've also found that, if you're not getting sufficient sleep in the week before you get your flu shot, you produce less than 50% of the normal antibody response, rendering that flu shot largely ineffective. We also know that your heart suffers.
So the antibodies are going to be specific for different pathogens, which we call antigens. So you have an antibody against cold virus. You have an antibody against HIV.
So you have an antibody against cold virus. You have an antibody against HIV. But you have many different antibodies against those two viruses because they could bind to different places on the HIV or on the cold virus.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. And so the antibody will clear the infection in an infant.
And so this was exciting. So their antibody is working-- at least, biochemically-- to remove plaques.
And so this was exciting. Aducanumab-- that Biogen antibody -- looks promising, but it was a small trial.
Since you kind of, perhaps more than most, have a spectrum of insight across what various companies are up to in academics? or targeted antibody therapies.
And you see them in the middle here of the cleaning cycle and someone back off about 20 or 30 meters who is recording the data And it's an antibody match.
Today, I think women have a large number of role models and examples of how successful women can be. And I'm very excited about these antibody treatments because they are very targeting when it comes to the virus.
that we face today, where all of humanity needs to pull together and row oars in the same boat. So the first project is the antibody cocktail. So if you've been following the news with the US President, he took an antibody cocktail in the last couple of days.
You have an infinite capacity to make a huge number of antibodies. And if you have an antibody that will neutralize the virus, it will prevent the virus from infecting its target cell. And then you won't have any of these viral progeny.
But it's really hard to be a nNAbs or a broadly neutralizing antibody . It's very easy to make an antibody that is strain specific. But to make one that binds to a lot of different strains is difficult. And the reason is that the spike actually
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. And so they're hidden from the antibody .
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. So we get the broadly neutralizing antibody from a patient, and then we try to be bio-engineers and make it even better.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. So it's a useless antibody .
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. And so they get an antibody to treat it.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. is that when you have an antibody , it's binding between spikes, so that one arm binds here and the other arm binds to an adjacent spike.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. So Elmo's like the antibody , and he's trying to hang onto this bar through whatever these things are.
So the one thing that gets squeezed like Vise-Grips in the middle of the night is this thing called a normal eight-hour sleep period. you only produce half of the normal antibody response, rendering that flu shot largely useless.
And you can actually measure this. You can measure the titer of an antibody response. And so that's what they did in these patients.
They looked at some patients who had no antibody titer against A beta, people who had an intermediate antibody titer, and patients who had high antibody titers against A beta. And they saw that there was actually a really tight association between that finding and the degree of amyloid plaques
But you can bypass that and, instead, engineer your own antibody . And we call that a monoclonal antibody when it's a single antibody that's manufactured in great abundance in a manufacturing facility like Genentech or AbbVie or one of these big companies has.
And so this was exciting. Aducanumab was the next big monoclonal antibody .
And so this was exciting. It turns out that their antibody does bind to the form of A beta that might cause those inflammatory reactions.
And so this was exciting. Because another reason why that Lilly antibody -- solanezumab-- might have failed, they used a fairly low dose of it.
that those of you who like meat, eggs, and dairy are four times more likely to die from diabetes. You see a significant improvement to protective antibody response, just a few extra servings of fruits and vegetables This wasn't cutting out meat or anything.
And when we've tested these in our mouse models and our pig models, we find that these caspase inhibitors can reduce the tiny number of islets needed We're going to give antibody treatments at the beginning to reset the immune system.
And these are the data. So the morning vaccination showed a really robust antibody response going from essentially 0 to 400. What about the afternoon group, between 3 o'clock and 5 o'clock in the afternoon?
So he really wanted to get vaccinated. Sometimes, depending on antibody levels and a couple of other specific factors, could have protection
Today, I think women have a large number of role models and examples of how successful women can be. And if we have got vaccines and if we have got antibody therapies and if we have got treatments, then I don't think anyone needs to be so scared.
This is why DARPA and the US military took it up in the first place. So we can have a kind of global network of localized antibody cocktail production that could reach orders of magnitude more than the current model. And the second project that we've been working on is repurposing.
So that's what you want. You want a vaccine that will raise an antibody like that. That's what we really want.
So these are the parts that would bind to the foreign thing, the new thing. And this is pretty much the same from one antibody to another. So the antibodies are going to be specific for different pathogens, which we call antigens.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. So that shows you how this is an antibody fragment.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. Or we can just try to make this antibody better, so that maybe HIV can't escape from it.
And so that's what they did in these patients. They looked at some patients who had no antibody titer against A beta, people who had an intermediate antibody titer, and patients who had high antibody titers against A beta.
And so this was exciting. So what they tried to do here-- they engineered their antibody so that it bound to a form of A beta that
So if you raise antibodies against HIV, they could actually be neutralizing, which means that-- some of them. If the right type of antibody would bind to, let's say, the spike right here, and it would interfere with attachment here, so you'd never get it infected.
One's called Fab, and that means fragment antigen binding. And that just means the antigen is what is seen by the antibody . And the other part is a constant part that's fragment constant, let's say.
by colored areas here. But it's really hard to be a nNAbs or a broadly neutralizing antibody . It's very easy to make an antibody that is strain specific.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. And so it doesn't-- people don't clear HIV infections with their antibody response.
And so if you cover yourself in carbohydrates, you're shielding yourself from antibodies. So we called it "Few and Far Between-- How HIV May Be Evading Antibody Avidity." so avidity is the ability to use both arms to bind.
And then we have another infusion to provide enough cell mass to make it sufficient insulin for the patient. Then we gave these two anti-rejection drugs-- sirolimus and tacrolimus-- and an antibody at the beginning. And we subsequently changed these drugs now to more standard drugs, because we encountered quite a lot of side effects from the sirolimus drug.
which is another way to look at it in more of a pendulum sense, right? Because we have this need, my stepfather used to say that the greatness of America was this, we build a better mouse trap idea. Well, that's the antibody idea, right? The pendulum swings and we have this obvious need. People can't figure out, fact from fiction. We're drowning in misinformation. Is there a need then that the better mouse trap can fulfill? I don't know the answer to the question. I just know that
A very big difference. In fact, there's about a threefold difference in antibody response compared to morning and afternoon. Whether this is going to also be the case for COVID-19, we don't know yet.
Today, I think women have a large number of role models and examples of how successful women can be. In COVID, spike protein is really the main antigen against which you want the antibody response.
Today, I think women have a large number of role models and examples of how successful women can be. And I know that, if you give one shot of that antibody treatment, actually you can just get rid of the virus.
So the first project is the antibody cocktail. So if you've been following the news with the US President, he took an antibody cocktail in the last couple of days. What it is is, when you recover from COVID, you may have antibodies coursing through your veins and arteries, and that can be transplanted to somebody else.